Loading clinical trials...

COMPLETEDPHASE3

Sertraline Compared With Hypericum Perforatum (St.John's Wort) in Treating Depression

A Phase III Double-Blind Randomized Trial Comparing Sertraline (Zoloft) And Hypericum Perforatum (St. John's Wort) In Cancer Patients With Mild To Moderate Depression

NCT00066859•Wake Forest University Health Sciences

View on ClinicalTrials.gov

Summary

RATIONALE: Antidepressants such as sertraline and the herb hypericum perforatum (St. John's wort) may be effective in treating mild to moderate depression. It is not yet known which treatment is more effective in improving depression in patients who have cancer. PURPOSE: This randomized phase III trial is studying how well sertraline works compared to St. John's wort in treating mild to moderate depression in patients with solid tumors.

Detailed Description

OBJECTIVES: * Compare the change in depression severity in cancer patients with mild to moderate depression treated with sertraline vs Hypericum perforatum. * Compare the severity of somnolence, nausea, and insomnia in patients treated with these regimens. * Compare the impact of these regimens on fatigue in these patients. * Correlate hyperforin concentrations with change in depression severity in patients treated with Hypericum perforatum. OUTLINE: This is a randomized, double-blind study. Patients are stratified according to level of depression (mild vs moderate), concurrent radiotherapy (yes vs no), and TNM stage (I, II, or III vs IV). Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive oral sertraline daily. * Arm II: Patients receive oral Hypericum perforatum daily. In both arms, treatment continues for 4 months in the absence of unacceptable toxicity. Measurements of depression, somnolence, nausea, insomnia, fatigue, and hyperforin concentration are assessed at baseline, and at 1, 2, and 4 months. PROJECTED ACCRUAL: A maximum of 250 patients will be accrued for this study.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Mild or moderate depression as determined by the following criteria (see Section 7.1 and 8.0)
•Mild : HRSD score 10-14; moderate: HRSD score 15-19 (Appendix IV)
•At least 2 of nine symptoms of depression on the PHQ (Appendix V)
•At least one of the nine PHQ symptoms must be either depressed/irritable mood or anhedonia
•Histologically or cytologically documented solid tumor, lymphoma, or primary or metastatic brain tumor \> 6 months from radiation with stable disease or no evidence of disease.
•Concurrent cancer chemotherapy with sertraline or St. John's wort is not allowed, therefore patients must have no plan for chemotherapy for 4 months
•Prior chemotherapy is allowed, but patients must be \>4 weeks from prior chemotherapy except \>6 weeks from prior mitomycin-C or nitrosourea
•Patients receiving Rituxin, Herceptin, Erbitux, Interferon, etc. are eligibile for this study while under treatment.
•Prior or concurrent radiation is allowed except brain irradiation for brain metastases or primary brain tumor. Must be \> 6 months from radiation with stable disease or no evidence of disease.
•Age \> 18 years
+5 more criteria

Exclusion Criteria

•A patient will be excluded if he/she is (a) judged to be severely depressed using the following criteria: HRSD score 20 or more or a positive score on PHQ item i (suicidal ideation) or (b) judged not to be depressed by a score of 9 or less on the HRSD or fewer than two PHQ items scored positively. A patient who is found to be severely depressed or suicidal, either on initial screening or during the trial will be referred for appropriate treatment.
•Psychotic symptoms, dementia, marked agitation requiring medication
•Current or previous alcohol or drug dependence
•Hematologic malignancy (i.e., leukemias, multiple myeloma)
•Planned chemotherapy in the next 4 months
•Antidepressant or St. John's wort use in the last 4 weeks
•Current or planned use of erythropoietin (Procrit®, Aranesp®)
•Current or planned use of theophylline, warfarin (except for central line prophylaxis), protease inhibitors used to treat AIDS, digoxin, cyclosporin, benzodiazepines (such as diazepam, alprazolam, etc), calcium-channel blockers (such as diltiazem, nifedipine, etc), coenzyme A reductase inhibitors (cholesterol lowering agents), macrolide antibiotics (such as azithromycin, erythromycin, clarithromycin, etc), griseofulvin, phenobarbital, phenytoin, rifampin, rifabutin, ketoconazole, fluconazole, itraconazole, corticosteroids, grapefruit juice, or other naturopathic/herbal products that could interfere with St. John's wort (call study chairman with questions).
•Pregnant or nursing women

Locations (6)

Bay Area Tumor Institute

Oakland, California, United States

Regional Radiation Oncology Center at Rome

Rome, Georgia, United States

CCOP - Central Illinois

Decatur, Illinois, United States

CCOP - Southeast Cancer Control Consortium

Goldsboro, North Carolina, United States

High Point Regional Hospital

High Point, North Carolina, United States

Comprehensive Cancer Center at Wake Forest University

Winston-Salem, North Carolina, United States

Key Dates

Start Date

March 1, 2004

Primary Completion Date

April 1, 2005

Completion Date

November 1, 2005

Last Updated

September 9, 2021

Enrollment

ACTUAL participants

Conditions

DepressionUnspecified Adult Solid Tumor, Protocol Specific

Interventions

Zoloft 50 mg

DRUG

St. John's Wort 600 mg

DIETARY_SUPPLEMENT

ACT Together: Implementing a Web-Based Program With Brief Coaching for Parents of Children With Disabilities in Pediatric Outpatient Clinics

NCT07360600

ParentsChildren With Disabilities+2 more

View study

RECRUITINGPHASE3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397

Major Depressive Disorder (MDD)Depression in Adults+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 9, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Sertraline Compared With Hypericum Perforatum (St.John's Wort) in Treating Depression

Inclusion Criteria

Exclusion Criteria

ACT Together: Implementing a Web-Based Program With Brief Coaching for Parents of Children With Disabilities in Pediatric Outpatient Clinics

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Readiness and Progress in Emotion Regulation Therapy

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression

Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures